FDA Issues Warning to Valeant Following Production Problems

Nov 09, 2016

The U.S. Food and Drug Administration issued a warning letter to Valeant following an inspection of its Rochester, New York, facility.

This is just the latest in a string of bad fortunes for the multinational specialty pharmaceutical company, which has seen its stocks fall, its ex-execs under probe and forced to sell critical assets.

The FDA noted various problems with Valeant's “SPAG-2” and “ONSET Mixing Pen” production such as a failure to establish and maintain procedures for validating device design and implementing corrective and preventive actions as required.

Read the FDA's letter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments